Abstract
The global incidence rate of cancer cases increases with 18 Mio. (2018) new diagnosis a year. Most patients get a standard therapy, which is often not the best fit. The key problem is that each patient and each tumor responses differently to drugs. Here we address solid tumor biopsies from colon cancer patients. We present high-throughput drug-screening, which allows to determine the efficiency of individual and combinatorial drugs, including antibodies, pathway inhibitors or cytokines to recommend the best personalized therapy for the patient.
| Original language | English |
|---|---|
| Title of host publication | MicroTAS 2020 - 24th International Conference on Miniaturized Systems for Chemistry and Life Sciences |
| Publisher | Royal Society of Chemistry |
| Pages | 270-271 |
| Number of pages | 2 |
| ISBN (Electronic) | 9781733419017 |
| Publication status | Published - 2020 |
| Event | 24th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2020 - Virtual, Online Duration: 4 Oct 2020 → 9 Oct 2020 |
Conference
| Conference | 24th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2020 |
|---|---|
| City | Virtual, Online |
| Period | 4/10/20 → 9/10/20 |
Funding
I acknowledge the funding of our technology on both, clinical applicability and commercialization, which has been recognized by the German Ministry of Economy and Energy by EXIST grant.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Best Personalized Therapy
- Cancer Cell Apoptosis
- Cell Signaling
- High-Throughput Drug Screening
Fingerprint
Dive into the research topics of 'Novel approach for advanced personalized cancer treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver